|Articles|June 5, 2023
- Pharmaceutical Executive: June 2023
- Volume 43
- Issue 6
Pharmaceutical Executive, June 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive June 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 3 years ago
2023 Pharm Exec Top 50 Companiesalmost 3 years ago
Great Leaders Listenalmost 3 years ago
Measuring Pharma’s Trust Performancealmost 3 years ago
Embracing Generative AI: Why Its Disruption is Positive for Pharmaalmost 3 years ago
Tapping NPs and PAs in Life Sciences Marketingalmost 3 years ago
The Quest to Fully Address Prescription Drug Affordabilityalmost 3 years ago
How Pharma Should Prepare for Looming Nursing Shortagealmost 3 years ago
Could a Rates Pivot By Fed Change Biotech’s Fate?almost 3 years ago
A Success Story for a Brand and for Women: 'Welcome to My Vagina'almost 3 years ago
New EU Proposals to Regulate Pharma Duck the Difficult QuestionsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5

